Receipt of deferred consideration

RNS Number : 5537H

Omega Diagnostics Group PLC

25 November 2022

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Receipt of deferred consideration

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the £4.0m of deferred consideration relating to the sale of the CD4 business.

Accordingly, as of close of business on 24 November 2022, Omega held cash balances of £6.5m.

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

Omega Diagnostics Group PLC	www.omegadiagnostics.com
Jag Grewal, Chief Executive	via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd	Tel: [phone]
Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane/ Harriet Ward (ECM)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen	Mob: [phone] / Mob: [phone]

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com

 

END

 

 

MSCFEFFMLEESEIF